(R)-2-Chlorobutanoic acid (CAS 54053-45-1) Market (2026): Top 10 Companies Driving Global Chiral Chemistry

MARKET INSIGHTS

The global (R)-2-Chlorobutanoic acid (CAS 54053-45-1) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(R)-2-Chlorobutanoic acid (CAS 54053-45-1) is a chiral alpha‑halo carboxylic acid characterized by its (R)-configuration at the second carbon position. This enantiomerically pure compound serves as a critical building block in asymmetric synthesis, particularly in the preparation of pharmaceutically active molecules, agrochemicals, and specialty fine chemicals. Its high optical purity and well‑defined stereochemistry make it an indispensable intermediate in chiral chemistry workflows.

The market is witnessing steady growth driven by rising demand for enantiopure intermediates in pharmaceutical synthesis and the expanding global fine chemicals industry. Furthermore, increasing adoption of chiral synthesis methodologies in drug development—particularly for active pharmaceutical ingredients (APIs) requiring strict stereochemical control—continues to fuel demand. Key suppliers operating in this space include Alfa Aesar, TCI Chemicals, and Sigma‑Aldrich (Merck KGaA), among other specialty chemical manufacturers maintaining robust product portfolios.

(R)-2-Chlorobutanoic acid (CAS 54053-45-1) Market – View in Detailed Research Report

Top 10 Companies in the (R)-2-Chlorobutanoic acid (CAS 54053-45-1) Market

1. Merck KGaA (Germany)

Headquarters: Darmstadt, Germany
Key Offering: High‑purity chiral intermediates, API synthesis support

Merck KGaA, through its Sigma‑Aldrich division, leverages advanced enantioselective synthesis platforms to deliver (R)-2‑Chlorobutanoic acid at scale. The company’s GMP‑compliant facilities ensure consistent optical purity, a critical factor for regulatory approvals in drug development.

Sustainability Initiatives:

• Implementation of closed‑loop recycling for chlorinated waste
• Investment in bio‑based precursor streams to reduce carbon footprint
• Targeted reduction of energy consumption by 15% across production lines

2. Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)

Headquarters: Tokyo, Japan
Key Offering: Specialty organic chemicals, chiral building blocks

TCI’s extensive portfolio of organic intermediates positions it as a reliable supplier of (R)-2‑Chlorobutanoic acid. The company’s focus on process optimization has led to higher yields in asymmetric reactions, reducing raw material costs for customers.

Sustainability Initiatives:

• Development of greener catalytic systems for chiral synthesis
• Partnerships with academic institutions for sustainable process research
• Commitment to zero‑waste manufacturing by 2035

3. Thermo Fisher Scientific Inc. (USA)

Headquarters: Waltham, Massachusetts, USA
Key Offering: Research chemicals, analytical solutions

Thermo Fisher’s strong presence in the research sector enables it to provide (R)-2‑Chlorobutanoic acid to academic and industrial laboratories, facilitating early‑stage drug discovery and process development.

Sustainability Initiatives:

• Implementation of green chemistry principles across product lines
• Investment in renewable energy for manufacturing sites
• Development of low‑toxic solvent systems for chiral reactions

4. Carbosynth Ltd. (UK)

Headquarters: Cambridge, United Kingdom
Key Offering: Custom synthesis, specialty chemicals

Carbosynth’s flexible synthesis capabilities allow it to tailor (R)-2‑Chlorobutanoic acid production to specific customer needs, supporting bespoke API development projects.

Sustainability Initiatives:

• Adoption of continuous flow chemistry to improve atom economy
• Use of recyclable solvents in chiral synthesis routes
• Collaboration with industry partners on green process innovation

5. Enamine LLC (Ukraine)

Headquarters: Kyiv, Ukraine
Key Offering: Chiral intermediates, contract manufacturing

Enamine’s expertise in asymmetric catalysis enables it to deliver high‑purity (R)-2‑Chlorobutanoic acid with competitive lead times, supporting global pharma clients.

Sustainability Initiatives:

• Implementation of waste‑minimisation protocols for chlorinated by‑products
• Use of renewable electricity for production facilities
• Engagement in circular economy projects with suppliers

6. PharmaBlock Sciences Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: High‑volume chiral intermediates, green chemistry solutions

PharmaBlock focuses on scalable production of (R)-2‑Chlorobutanoic acid, integrating green chemistry practices to meet the growing demand from generic drug manufacturers.

Sustainability Initiatives:

• Adoption of biocatalytic processes to reduce hazardous reagents
• Investment in carbon‑neutral production facilities
• Partnerships with local universities for sustainable synthesis research

7. Oakwood Products Inc. (USA)

Headquarters: Houston, Texas, USA
Key Offering: Specialty chemicals, contract manufacturing

Oakwood’s robust manufacturing infrastructure supports the supply of (R)-2‑Chlorobutanoic acid to a range of pharmaceutical and agrochemical customers, with a focus on consistent quality and rapid turnaround.

Sustainability Initiatives:

• Implementation of advanced waste‑water treatment systems
• Use of renewable energy sources in production plants
• Commitment to reducing overall carbon emissions by 20% by 2030

8. Hairui Fine Chemicals Co., Ltd. (China)

Headquarters: Shenzhen, China
Key Offering: High‑purity chiral intermediates, green chemistry expertise

Hairui specializes in the synthesis of enantiopure acids, employing catalytic systems that minimize waste and enhance yield, aligning with global sustainability trends.

Sustainability Initiatives:

• Development of solvent‑free chiral synthesis routes
• Investment in renewable energy for manufacturing sites
• Collaboration with industry partners on waste‑reduction technologies

9. Biosynth AG (Switzerland)

Headquarters: Basel, Switzerland
Key Offering: Custom synthesis, high‑purity intermediates

Biosynth’s precision manufacturing capabilities allow it to produce (R)-2‑Chlorobutanoic acid with optical purities exceeding 99.5%, catering to the most demanding pharmaceutical applications.

Sustainability Initiatives:

• Implementation of closed‑loop water recycling systems
• Use of renewable electricity for all production processes
• Active participation in European green chemistry initiatives

10. Ningbo Inno Pharmchem Co., Ltd. (China)

Headquarters: Ningbo, China
Key Offering: Large‑scale chiral intermediates, process innovation

Ningbo Inno Pharmchem leverages advanced catalytic technologies to deliver (R)-2‑Chlorobutanoic acid at high throughput, supporting both domestic and international customers.

Sustainability Initiatives:

• Adoption of energy‑efficient continuous flow processes
• Use of bio‑derived feedstocks for chiral synthesis
• Commitment to zero‑waste production by 2035

Download FREE Sample Report

Get Full Report Here

Outlook

The (R)-2‑Chlorobutanoic acid market is positioned for continued expansion as pharmaceutical and agrochemical sectors deepen their reliance on chiral intermediates. The convergence of increased R&D spending in drug discovery, coupled with the global push for single‑enantiomer therapeutics, fuels demand for high‑purity building blocks. Meanwhile, the adoption of continuous flow and biocatalytic processes is expected to lower production costs and enhance scalability, thereby broadening market participation beyond large‑scale manufacturers.

Future Trends

• Growth in biotechnology applications, particularly for peptide and biologic conjugates, will drive new demand for (R)-2‑Chlorobutanoic acid.
• Advances in asymmetric catalysis, including organocatalysts and engineered enzymes, will improve yields and reduce reliance on hazardous reagents.
• Regulatory emphasis on environmental sustainability is likely to accelerate the shift toward greener synthesis routes, fostering innovation in solvent‑free and bio‑based processes.
• Emerging markets in Asia‑Pacific, especially China and India, are expected to capture a larger share of production capacity, supported by government incentives for specialty chemical development.